Obesity is a major metabolic disorder associated with an increased risk of type 2 diabetes, cardiovascular disease, hypertension, fatty liver disease, and metabolic syndrome.

Adipose tissue was previously considered primarily a storage site for excess energy.

It is now recognized as an important endocrine organ that releases numerous signaling molecules.

These molecules, collectively known as adipokines, influence metabolism, appetite, inflammation, vascular function, and insulin sensitivity.

In healthy adipose tissue, adipokines contribute to the maintenance of metabolic balance.

During obesity, adipose tissue undergoes structural and functional changes.

These changes can alter adipokine secretion and promote chronic low-grade inflammation.

The resulting imbalance may contribute to systemic insulin resistance and other metabolic complications.

Major Adipokines and Their Functions

Different adipokines have distinct and sometimes opposing biological functions.

Adiponectin and Metabolic Protection

Adiponectin is one of the most extensively studied adipokines.

Unlike several inflammatory adipokines, circulating adiponectin concentrations often decrease as adiposity increases.

Adiponectin enhances insulin sensitivity and promotes fatty-acid oxidation.

It also has anti-inflammatory and vascular protective effects.

Reduced adiponectin may therefore contribute to insulin resistance and increased cardiovascular risk in obesity.

The relationship between adiponectin and metabolic health has made it an important candidate biomarker for metabolic dysfunction.

Leptin and Leptin Resistance

Leptin is primarily produced by adipocytes and plays an important role in regulating appetite and energy expenditure.

Increased adipose tissue generally results in increased circulating leptin concentrations.

However, obesity is frequently associated with reduced biological responsiveness to leptin, a condition known as leptin resistance.

When leptin signaling becomes impaired, appetite regulation and energy homeostasis may be disrupted.

Leptin can also influence inflammatory and immune pathways, providing another connection between obesity and chronic inflammation.

Pro-Inflammatory Adipokines

Obesity is associated with increased production of several inflammatory mediators.

Tumor necrosis factor-alpha and interleukin-6 can interfere with insulin signaling and contribute to systemic inflammation.

Persistent inflammatory signaling may impair glucose uptake in skeletal muscle and alter hepatic glucose metabolism.

This contributes to the development of insulin resistance.

Inflammatory adipokines may also promote endothelial dysfunction and increase cardiovascular risk.

Adipokines and Insulin Resistance

Adipokine imbalance is closely associated with impaired insulin action.

Reduced adiponectin can decrease fatty-acid oxidation and insulin sensitivity.

Increased inflammatory signaling can interfere with insulin receptor substrate and downstream PI3K-AKT pathways.

Excess fatty-acid release from dysfunctional adipose tissue can further contribute to lipid accumulation in liver and muscle.

These mechanisms collectively promote systemic insulin resistance.

Adipokines in Obesity-Associated Disorders

This article was prepared as a concise narrative review of scientific literature addressing adipokine biology and obesity-associated metabolic disorders.

Relevant research concerning adiponectin, leptin, inflammatory adipokines, insulin resistance, obesity, metabolic syndrome, cardiovascular disease, and fatty liver disease was considered.

The available evidence was synthesized to describe the principal mechanisms through which adipokine dysregulation contributes to metabolic disease.

Results

The reviewed evidence indicates that obesity significantly alters adipose tissue endocrine function.

Reduced adiponectin and impaired leptin signaling are important features of adipose dysfunction.

Increased inflammatory mediators further contribute to impaired insulin signaling and systemic inflammation.

Adipokine dysregulation therefore provides a molecular connection between excess adiposity and several metabolic complications, including type 2 diabetes, metabolic syndrome, cardiovascular disease, and fatty liver disease.

Adipokines provide an important molecular link between adipose tissue and distant organs.

Their effects extend beyond energy storage and include regulation of glucose metabolism, lipid oxidation, inflammation, vascular function, and appetite.

One of the most important changes associated with obesity is the imbalance between protective and pro-inflammatory adipokines.

Reduced adiponectin may contribute to decreased insulin sensitivity, while increased inflammatory signaling can further disrupt metabolic pathways.

Leptin resistance represents another important mechanism.

Although leptin concentrations are generally elevated in obesity, the expected reduction in appetite and increase in energy expenditure do not occur adequately.

This suggests that impaired signaling, rather than a simple deficiency of leptin, contributes to obesity-associated metabolic dysfunction.

Adipokines may also influence communication between adipose tissue and the liver.

Increased fatty-acid delivery and inflammatory signaling can promote hepatic lipid accumulation and metabolic dysfunction.

Similarly, adipokine-mediated vascular inflammation may contribute to endothelial dysfunction and cardiovascular disease.

These observations suggest that adipokines could serve both as biomarkers and potential therapeutic targets.

However, adipokine concentrations can be influenced by age, sex, body composition, physical activity, diet, and other metabolic factors.

Further research is therefore needed to determine whether modifying individual adipokine pathways can produce clinically meaningful improvements.

Therapeutic Perspectives

Potential strategies for targeting adipokine-related pathways include weight reduction, physical activity, dietary modification, and pharmacological interventions that improve insulin sensitivity.

Because adipokine dysregulation is closely connected with adipose tissue dysfunction, improving overall metabolic health may restore a more favorable adipokine profile.

Future therapies may focus on specific adipokine receptors, signaling pathways, or combinations of metabolic targets.

Adipokines play an important role in regulating the relationship between adipose tissue and systemic metabolism.

Obesity disrupts normal adipokine secretion, resulting in reduced protective signaling and increased inflammatory activity.

These changes contribute to insulin resistance, type 2 diabetes, metabolic syndrome, cardiovascular disease, and fatty liver disease.

Adiponectin and leptin are particularly important regulators, while inflammatory adipokines further amplify metabolic dysfunction.

Improved understanding of adipokine signaling may support the development of new biomarkers and targeted therapeutic approaches for obesity-associated metabolic disorders.

1. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. Journal of Clinical Endocrinology & Metabolism. 2004;89:2548–2556.
2. Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes. 2006;55:1537–1545.
3. Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia. 2012;55:2319–2326.
4. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends in Endocrinology and Metabolism. 2000;11:327–332.
5. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nature Reviews Immunology. 2011;11:85–97.
6. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. British Journal of Nutrition. 2004;92:347–355.
7. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860–867.
8. Blüher M, Mantzoros CS. From leptin to other adipokines in health and disease: facts and expectations at the beginning of the third millennium. Metabolism. 2015;64:131–145.